Johnson & Johnson announced a commitment of more than $1 billion to build a new cell‑therapy manufacturing facility in Lower Gwynedd Township, Montgomery County, Pennsylvania. The project is part of the company’s broader $55 billion U.S. investment plan that will expand manufacturing, research and development, and technology through early 2029.
The new plant is expected to create more than 500 biomanufacturing jobs once it is fully operational, and it will generate over 4,000 construction jobs during its development phase. The investment is intended to strengthen J&J’s domestic manufacturing capacity and support the company’s pipeline of transformational medicines for cancer, immune‑mediated, and neurological diseases.
By expanding cell‑therapy manufacturing in the United States, J&J aims to meet growing demand for advanced therapies, reduce supply‑chain risk, and accelerate the delivery of new treatments to patients. The facility will play a key role in the company’s strategy to bring cutting‑edge cell‑based medicines to market more efficiently.
J&J’s Q4 2025 results—sales of $24.6 billion, a 9.1% year‑over‑year increase, and adjusted earnings per share of $2.46—demonstrate the financial strength that underpins this investment. The company’s guidance for 2026 projects sales of $100.5 billion and adjusted EPS of $11.53, underscoring confidence in continued growth and the ability to fund large capital projects.
J&J Chairman and CEO Joaquin Duato said, “By uniting scientific excellence with state‑of‑the‑art manufacturing and strategic investment, and by working collaboratively with our communities, we are delivering for patients and creating significant opportunities for workers and families.” He added, “For 140 years, Johnson & Johnson has been a leading innovator in American healthcare, and we are honored to continue advancing that legacy in Pennsylvania.”
The company has not yet disclosed a specific timeline for the plant’s completion or the particular cell‑therapy technologies that will be employed, but the investment aligns with its long‑term strategy to expand domestic production of high‑growth therapies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.